FINANCIAL STATEMENT ANALYSIS

USED BY US DEPARTMEN OF EDUCATION, UNIVERSITIES, STUDENTS & ACCOUNTING PRO'S

VentureLine tracks and provides 5-year financial statement analysis on approximately 7,000+ publicly traded companies; the SEC-traceable data is updated weekly. For your convenience you can access that current company financial statement analysis information by clicking directly on the Company Name, visit their Website or enter the Company name or Ticker symbol, e.g. enter 'Microsoft' or 'MSFT' for Microsoft, in the Company Search window below.

FINANCIAL STATEMENT ANALYSIS UPDATED: JULY 24, 2022

Results 301 through 322 of 322

BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES - SIC # 2836

Ticker Exchange Company Financial Reports SIC #
TVRD Nasdaq Tvardi Therapeutics, Inc. 2836
TWST Nasdaq Twist Bioscience Corporation 2836
TXG Nasdaq 10x Genomics, Inc. 2836
UPB Nasdaq Upstream Bio, Inc. 2836
VIVS Nasdaq VivoSim Labs, Inc. 2836
VKTX Nasdaq Viking Therapeutics, Inc. 2836
VOR Nasdaq Vor Biopharma Inc. 2836
VSTM Nasdaq Verastem, Inc. 2836
VTGN Nasdaq Vistagen Therapeutics, Inc. 2836
VTYX Nasdaq Ventyx Biosciences, Inc. 2836
WHWK Nasdaq Whitehawk Therapeutics, Inc. 2836
XAGE Nasdaq Longevity Health Holdings, Inc. 2836
XBIT Nasdaq XBiotech Inc. 2836
XCUR Nasdaq Exicure, Inc. 2836
XENE Nasdaq Xenon Pharmaceuticals Inc. 2836
XGN Nasdaq Exagen Inc. 2836
XOMA Nasdaq XOMA Royalty Corporation 2836
XTLB Nasdaq XTL Biopharmaceuticals Ltd. 2836
YMAB Nasdaq Y-mAbs Therapeutics, Inc. 2836
ZBIO Nasdaq Zenas BioPharma, Inc. 2836
ZNTL Nasdaq Zentalis Pharmaceuticals, Inc. 2836
ZTS New York Zoetis Inc. 2836
Results 300 through 322 of 322